Explore 3 Stock Ideas & Industry Insights Download Free Report

Telescope Innovations Corp.

Healthcare CA TELI

0.89CAD
0.06(7.23%)

Last update at 2026-06-24T15:54:00Z

Day Range

0.800.89
LowHigh

52 Week Range

0.230.65
LowHigh

Fundamentals

  • Previous Close 0.83
  • Market Cap30.71M
  • Volume38338
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.34016M
  • Revenue TTM7.11M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 7.11M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -1.56281M -1.32365M -0.71809M -5.74703M -4.02532M
Minority interest - - - - -
Net income -1.56281M -1.32365M -0.71809M -5.72728M -4.02703M
Selling general administrative 4.44M 2.97M 2.33M 5.60M 3.72M
Selling and marketing expenses - - - 0.01M 0.00490M
Gross profit - - 2.82M 0.60M -0.01565M
Reconciled depreciation 0.72M 0.63M 0.30M 0.28M 0.00000M
Ebit - - - -5.76677M -
Ebitda - - - -5.49043M -4.02190M
Depreciation and amortization - - - 0.28M -
Non operating income net other - - - - -
Operating income -1.34817M -1.04634M -0.72174M -5.76677M -4.02190M
Other operating expenses - - - 6.35M 4.02M
Interest expense 0.25M 0.24M 0.00000M 0.02M -
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.25337M -0.23654M 0.00000M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -0.01975M 0.00171M
Total revenue 4.78M 4.27M 2.82M 0.60M 0.00000M
Total operating expenses 6.13M 5.31M 3.55M 6.35M 4.02M
Cost of revenue - - 0.00350M 0.93M 0.02M
Total other income expense net 0.04M -0.04077M 0.00364M 0.02M -0.00342M
Discontinued operations - - - - -
Net income from continuing ops -1.56281M -1.32365M -0.71809M -5.74703M -4.02532M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 7.28M 5.69M 3.29M 3.02M 4.07M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - 0.06M -
Total liab 5.27M 4.17M 0.71M 1.35M 0.25M
Total stockholder equity 2.00M 1.52M 2.58M 1.67M 3.83M
Deferred long term liab - - - - -
Other current liab - - - 0.04M -
Common stock - - - 8.95M 8.10M
Capital stock 10.34M 10.34M 10.34M 8.95M 8.10M
Retained earnings -13.62922M -12.06640M -10.74275M -10.02466M -4.27830M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 2.70M 0.34M 0.36M 0.72M 3.29M
Cash and equivalents - - - - -
Total current liabilities 3.16M 2.15M 0.71M 1.35M 0.25M
Current deferred revenue - - - 0.83M -
Net debt - - - -0.71949M -3.29439M
Short term debt - - - - -
Short long term debt 1.21M - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets 3.84M 2.41M 1.21M 1.50M 3.47M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.20M 1.55M 0.22M 0.72M 0.06M
Long term debt - - - - -
Inventory 0.60M 0.30M 0.25M 0.00000M -
Accounts payable 1.15M 0.40M 0.18M 0.48M 0.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - 2.74M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 3.43M 3.29M 2.08M 1.53M 0.60M
Capital lease obligations 2.25M 2.03M 0.00000M - -
Long term debt total - - - - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments - -0.03960M -0.03576M -1.20373M -0.59957M
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings 1.21M 0.00000M - 0.00000M -0.00707M
Total cash from financing activities 3.04M 0.00000M 1.43M 0.00000M 4.79M
Change to operating activities - - - - -
Net income -1.56281M -1.32365M -0.71809M -5.74703M -4.02532M
Change in cash 2.36M -0.01980M -0.36268M -2.57490M 3.25M
Begin period cash flow 0.34M 0.36M 0.72M 3.29M 0.05M
End period cash flow 2.70M 0.34M 0.36M 0.72M 3.29M
Total cash from operating activities 0.25M 0.02M -1.75697M -1.37116M -0.94100M
Issuance of capital stock - 0.00000M 1.43M 0.00000M 4.79M
Depreciation 0.72M 0.63M 0.30M 0.28M 0.00000M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.29259M -0.05632M -0.24860M 0.00000M -
Change to account receivables 1.35M -1.32577M 0.28M -0.50395M 0.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -1.20373M 0.00025M
Change to netincome - - - - -
Capital expenditures 0.92M 0.04M 0.04M 1.20M 0.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.87M 0.45M -1.53532M 0.51M -0.02545M
Stock based compensation 0.22M 0.26M 0.19M 2.74M 0.05M
Other non cash items - - - 0.85M 3.06M
Free cash flow -0.67266M -0.01980M -1.79274M -2.57490M -1.54056M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TELI
Telescope Innovations Corp.
0.06 7.23% 0.89 - - 4.32 6.45 4.32 -1.62
DRUG
Bright Minds Biosciences Inc
-0.85 0.90% 94.04 - - - 13.50 -0.098
METX
METX
- -% 1.99 - - - 72.00
DTC
Defence Therapeutics Inc
-0.04 7.27% 0.51 - - - 89.80 -9.991
LOBE
Lobe Sciences Ltd
- -% 0.09 - - 2.44 15.58 5.75 1.64

Reports Covered

Stock Research & News

Profile

Telescope Innovations Corp., a chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada. It offers DIRECTINJECT-LCTM, a hardware and software ecosystem that enables direct sampling and analysis of chemical reactions. It also provides intellectual property and contract research services. It serves pharmaceutical, critical minerals, and chemical industries. Telescope Innovations Corp. has a research collaboration with Pfizer Inc; and Standard Lithium Ltd. to develop a method for producing high-purity lithium sulfide. Telescope Innovations Corp. has a development and collaboration agreement with AGI Group's Synthesis, Digitization, and Automation program to develop the next generation of automation- and AI-ready chemical reactor technology. Telescope Innovations Corp. is based in Vancouver, Canada.

Telescope Innovations Corp.

301 - 2386 East Mall, Vancouver, BC, Canada, V6T 1Z3

Key Executives

Name Title Year Born
Mr. Henry Dubina CEO & Chairman of Board NA
Mr. John Kirincic Chief Financial Officer NA
Prof. Jason Hein CTO & Director NA
Ms. Vaso Vlachos Chief Operating Officer NA
Shad Grunert Senior VP of Sales & Marketing NA
Ms. Deborah Cotter Company Secretary NA
Mr. Jerry Chu Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions